The companies, along with the European Union Horizon 2020-sponsored Prevent-nCoV consortium partners, will use AdaptVac's virus-like particle technology to develop the vaccine. This technology makes ideal scaffolds for displaying vaccine antigens due to their particulate nature and dense repetitive subunit organization, according to the companies.

Clinical trials are expected to begin in late-2020.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Integral Molecular wins COVID-19 NIAID award
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to help discover vaccines and therapeutics...

MilliporeSigma, Jenner Institute partner on COVID-19 vaccine
MilliporeSigma and the Jenner Institute have announced that they are preparing for large-scale manufacturing of the COVID-19 vaccine candidate ChAdOx1...

Could a MERS vaccine candidate be the answer for COVID-19?
As researchers urgently work to develop vaccines to prevent COVID-19, many strategies have been considered. Now, a parainfluenza virus 5-based vaccine...

Pfizer, BioNTech give details about mRNA COVID-19 vaccine deal
Biopharmaceutical New Technologies (BioNTech) and Pfizer have released additional details regarding their collaboration to advance the mRNA COVID-19 vaccine...